Novo Nordisk A/S (NYSE:NVO) is one of the best affordable growth stocks to buy. In a report released on August 29, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO) with a price target of DKK340.00.
Novo Nordisk A/S announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion.
Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER).
Novo Nordisk A/S is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.
Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
